0001193125-20-081568.txt : 20200323 0001193125-20-081568.hdr.sgml : 20200323 20200323075212 ACCESSION NUMBER: 0001193125-20-081568 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200323 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200323 DATE AS OF CHANGE: 20200323 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 20733596 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 8-K 1 d881179d8k.htm 8-K 8-K
NY false 0001567514 0001567514 2020-03-23 2020-03-23

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 23, 2020

 

Intra-Cellular Therapies, Inc.

(Exact name of registrant as specified in its charter)

 

Commission File Number: 001-36274

Delaware

  

36-4742850

(State or other jurisdiction

of incorporation)

  

(IRS Employer

Identification No.)

430 East 29th Street

New York, NY 10016

(Address of principal executive offices, including zip code)

(646) 440-9333

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

Trading Symbol(s)

  

Name of each exchange on which registered

Common Stock

  

ITCI

  

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

ITEM 8.01 Other Events.

On March 23, 2020, Intra-Cellular Therapies, Inc. (the “Company”) announced that CAPLYTA (lumateperone) is now available to pharmacies in the U.S. CAPLYTA is an oral, once daily medicine approved for the treatment of schizophrenia in adults.

The Company’s press release announcing the approval is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

In addition, the global spread of a novel strain of coronavirus, SARS-CoV-2, which causes coronavirus disease 2019 (COVID-19), as well as the Company’s actions to protect the health of its employees and the healthcare providers and patients it serves, and their families and communities, create a number of risks and uncertainties to the Company’s business which could have a material adverse effect on its business, results of operations and financial condition, described further below:

The outbreak of the novel strain of coronavirus, SARS-CoV-2, or similar public health crises, could have a material adverse impact on our business, financial condition and results of operations, including our commercial operations and sales, clinical trials and preclinical studies.

Public health crises, such as pandemics or similar outbreaks, could adversely impact our business. In December 2019, a novel strain of coronavirus, SARS-CoV-2, which causes coronavirus disease 2019 (COVID-19), surfaced in Wuhan, China. Since then, SARS-CoV-2 and COVID-19 have spread to multiple countries, including the United States. The COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. In response to the spread of SARS-CoV-2 and COVID-19, we have instructed the majority of our office-based employees to work from home. In connection with our commercial launch of CAPLYTA, which is approved by U.S. Food and Drug Administration for the treatment of schizophrenia in adults, our commercial organization and sales force and medical organization may have significantly reduced personal interactions with physicians and customers and increasingly conduct promotional activities virtually, and we may elect to cease in-person interactions with physicians and customers entirely for some period of time in the interest of employee and community safety. As a result of the COVID-19 outbreak, or similar pandemics, we may experience disruptions that could severely impact our business, including our ability to successfully commercialize our only commercial product, CAPLYTA, in the U.S., and these disruptions could negatively impact our sales of CAPLYTA. Business interruptions from the current or future pandemics may also adversely impact the third parties we rely on to sufficiently manufacture CAPYLTA and to produce our product candidates in quantities we require, which may impair the commercialization and our research and development activities.

We are currently conducting clinical trials for our product candidates in many countries, including the United States, Europe and Russia and may expand to other geographies. Timely enrollment of, completion of and reporting on our clinical trials is dependent upon these global clinical trial sites which are, or in the future may be, adversely affected by the COVID-19 outbreak or other pandemics. Some factors from the COVID-19 outbreak that may adversely affect the timing and conduct of our clinical trials and adversely impact our business generally, include but are not limited to delays or difficulties in clinical site initiation, diversion of healthcare resources away from clinical trials to pandemic concerns, limitations on travel, regulatory delays and supply chain disruptions.

The COVID-19 outbreak continues to rapidly evolve, and the extent to which the outbreak impacts our business, including our commercial results, clinical trials, and preclinical studies will depend on future developments, which are highly uncertain.

ITEM 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number

   

Description

         
 

99.1

   

Press release dated March 23, 2020

         
 

104

    

Cover Page Interactive Data File (embedded within the Inline XBRL document)

The press release may contain hypertext links to information on our website. The information on our website is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTRA-CELLULAR THERAPIES, INC.

     

By:

 

/s/ Lawrence J. Hineline

 

Lawrence J. Hineline

 

Senior Vice President of Finance, Chief Financial Officer, Treasurer and Assistant Secretary

Date: March 23, 2020

EX-99.1 2 d881179dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia

NEW YORK, March 23, 2020 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA (lumateperone) is now available to pharmacies in the U.S. CAPLYTA is an oral, once daily medicine approved for the treatment of schizophrenia in adults.

 

LOGO

“At Intra-Cellular Therapies, we understand the lifelong debilitating struggle people with schizophrenia experience. The need for new treatment options for this community has driven our efforts to bring CAPLYTA to market,” said Mark Neumann, Chief Commercial Officer of Intra-Cellular Therapies. “We have an experienced commercial team and have developed a comprehensive strategy with a multi-channel promotional plan to support the launch of CAPLYTA in light of the ongoing COVID-19 pandemic. In addition, affordability support programs are available to eligible CAPLYTA patients.”

The efficacy of CAPLYTA 42 mg was demonstrated in two placebo-controlled trials, showing a statistically significant benefit over placebo on the primary endpoint, the Positive and Negative Syndrome Scale (PANSS) total score. The most common adverse reactions (³5% and twice the rate of placebo) for the recommended dose of CAPLYTA vs. placebo were somnolence/sedation (24% vs.10%) and dry mouth (6% vs. 2%). In pooled data from short term studies, mean changes from baseline in weight gain, fasting glucose, triglycerides and total cholesterol were similar between CAPLYTA and placebo. The incidence of extrapyramidal symptoms was 6.7% for CAPLYTA and 6.3% for placebo.

We recognize this is an extraordinary and challenging time with COVID-19; we are monitoring developments closely and we will adapt our approach as appropriate. To complement our current launch plan, we have developed remote capabilities for detailing, sampling and peer to peer interactions designed to ensure physicians are properly educated on CAPLYTA. We will also rely more heavily on digital promotion to augment the remote interactions of our sales colleagues.

We have substantial product supply in the U.S. with long expiry dating to support expected demand. Each 30-capsule pack of CAPLYTA covers once daily dosing for one month. Sample packs of 10 capsules are available for healthcare professionals. More information about CAPLYTA is available at 888-252-ITCI or at CAPLYTA.com.

Important Safety Information

Boxed Warning: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis.

Contraindications: CAPLYTA is contraindicated in patients with known hypersensitivity to lumateperone or any components of CAPLYTA.

Warnings & Precautions: Antipsychotic drugs have been reported to cause:

 

  •  

Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis, including stroke and transient ischemic attack. See BOXED WARNING above.

 

  •  

Neuroleptic Malignant Syndrome, which is a potentially fatal reaction. Signs and symptoms include: hyperpyrexia, muscle rigidity, delirium, autonomic instability, elevated creatinine phosphokinase, myoglobinuria (and/or rhabdomyolysis), and acute renal failure. Manage with immediate discontinuation of CAPLYTA and close monitoring.

 

  •  

Tardive Dyskinesia, a syndrome of potentially irreversible, dyskinetic, and involuntary movements which may increase as the duration of treatment and total cumulative dose increases. Discontinue CAPLYTA if clinically appropriate.

 

  •  

Metabolic Changes, including hyperglycemia, diabetes mellitus, dyslipidemia, and weight gain. Measure weight and assess fasting plasma glucose and lipids when initiating CAPLYTA and monitor periodically during long-term treatment.

 

  •  

Leukopenia, Neutropenia, and Agranulocytosis (including fatal cases). Perform complete blood counts in patients with pre-existing low white blood cell count (WBC) or history of leukopenia or neutropenia. Discontinue CAPLYTA if clinically significant decline in WBC occurs in absence of other causative factors.

 

  •  

Orthostatic Hypotension and Syncope. Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease.

 

  •  

Falls. CAPLYTA may cause somnolence, postural hypotension, and motor and/or sensory instability, which may lead to falls and, consequently, fractures and other injuries. Assess patients for risk when using CAPLYTA.

  •  

Seizures. Use CAPLYTA cautiously in patients with a history of seizures or with conditions that lower seizure threshold.

 

  •  

Potential for Cognitive and Motor Impairment. Advise patients to use caution when operating machinery or motor vehicles until they are reasonably certain CAPLYTA therapy does not affect them adversely.

 

  •  

Body Temperature Dysregulation. Use CAPLYTA with caution in patients who may experience conditions that may increase core body temperature such as strenuous exercise, extreme heat, dehydration, or concomitant anticholinergics.

 

  •  

Dysphagia. Use CAPLYTA with caution in patients at risk for aspiration.

Drug Interactions: Avoid concomitant use with CYP3A4 inducers and moderate or strong CYP3A4 inhibitors.

Special Populations: Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Breastfeeding is not recommended. Avoid use in patients with moderate or severe hepatic impairment.

Adverse Reactions: The most common adverse reactions in clinical trials with CAPLYTA vs. placebo were somnolence/sedation (24% vs. 10%) and dry mouth (6% vs. 2%).

Please click here to see full Prescribing Information including Boxed Warning.

About CAPLYTA (lumateperone)

CAPLYTA is an oral, once daily medicine approved for the treatment of schizophrenia of adults (42mg/day).

The mechanism of action of CAPLYTA in the treatment of schizophrenia is unknown. However, the efficacy of CAPLYTA could be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors.

CAPLYTA is being developed for the treatment of bipolar depression, behavioral disturbances in patients with dementia, including Alzheimer’s disease, depression and other neuropsychiatric and neurological disorders. CAPLYTA has not been demonstrated to be safe and effective in these other areas.

About Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, our expectations regarding our commercialization of CAPLYTA, including the impact of COVID-19 on the commercialization of CAPLYTA and our ability to adapt our approach as appropriate, the sales force that we expect to deploy and the promotional efforts we expect to utilize in support of the product; the supply and availability of and demand for our product, and our beliefs about the potential utility of our product candidates; and development efforts and plans under the caption “About Intra-Cellular Therapies.” All such forward-looking statements are based on management’s present expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, the following: there are no guarantees that CAPLYTA will be commercially successful; we may encounter issues, delays or other challenges in launching or commercializing CAPLYTA; the COVID-19 pandemic may negatively impact our commercial plans and sales for CAPLYTA; the COVID-19 pandemic may negatively impact the conduct of, and the timing of enrollment, completion and reporting with respect to, our clinical trials, whether CAPLYTA receives adequate reimbursement from third-party payors; the degree to which CAPLYTA receives acceptance from patients and physicians for its approved indication; challenges associated with execution of our sales activities, which in each case could limit the potential of our product; results achieved in CAPLYTA in the treatment of schizophrenia once we have launched the product may be different than observed in clinical trials, and may vary among patients; any other impacts on our business as a result of or related to the COVID-19 pandemic; risks associated with our current and planned clinical trials; we may encounter unexpected safety or tolerability issues with CAPLYTA for the treatment of schizophrenia or in ongoing or future trials and other development activities; our other product candidates may not be successful or may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials; our proposals with respect to the regulatory path for our product candidates may not be acceptable to the FDA; our reliance on collaborative partners and other third parties for development of our product candidates; and the other risk factors detailed in our public filings with the Securities and Exchange Commission. All statements contained in this press release are made only as of the date of this press release, and we do not intend to update this information unless required by law.

Contact:

Intra-Cellular Therapies, Inc.

Juan Sanchez, M.D.

Vice President, Corporate Communications and Investor Relations

646-440-9333

Burns McClellan, Inc.

Lisa Burns

jgrimaldi@burnsmc.com

212-213-0006

MEDIA INQUIRIES:

Ana Fullmer

Corporate Media Relations W2Owcg

afullmer@wcgworld.com

202-507-0130

EX-101.SCH 3 itci-20200323.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 itci-20200323_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Address, State or Province Entity Address, State or Province Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 itci-20200323_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g881179g0321032234983.jpg GRAPHIC begin 644 g881179g0321032234983.jpg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end ZIP 7 0001193125-20-081568-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-081568-xbrl.zip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end XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 d881179d8k_htm.xml IDEA: XBRL DOCUMENT 0001567514 2020-03-23 2020-03-23 NY false 0001567514 8-K 2020-03-23 Intra-Cellular Therapies, Inc. 001-36274 DE 36-4742850 430 East 29th Street New York 10016 (646) 440-9333 false false false false Common Stock ITCI NASDAQ false XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d881179d8k.htm d881179dex991.htm itci-20200323.xsd itci-20200323_lab.xml itci-20200323_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false XML 12 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information
Mar. 23, 2020
Cover [Abstract]  
Entity Address, State or Province NY
Amendment Flag false
Entity Central Index Key 0001567514
Document Type 8-K
Document Period End Date Mar. 23, 2020
Entity Registrant Name Intra-Cellular Therapies, Inc.
Entity File Number 001-36274
Entity Incorporation State Country Code DE
Entity Tax Identification Number 36-4742850
Entity Address, Address Line One 430 East 29th Street
Entity Address, City or Town New York
Entity Address, Postal Zip Code 10016
City Area Code (646)
Local Phone Number 440-9333
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock
Trading Symbol ITCI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d881179d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d881179d8k.htm" ] }, "labelLink": { "local": [ "itci-20200323_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "itci-20200323_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "itci-20200323.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "itci", "nsuri": "http://www.intracellulartherapies.com/20200323", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d881179d8k.htm", "contextRef": "duration_2020-03-23_to_2020-03-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d881179d8k.htm", "contextRef": "duration_2020-03-23_to_2020-03-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.intracellulartherapies.com//20200323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } EXCEL 16 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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